Christian Klemt Sells 10,438 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 10,438 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This trade represents a 4.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The shares were sold at an average price of $11.32, for a total value of $33,009.12.
• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The stock was sold at an average price of $10.70, for a total value of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Stock Performance

uniQure stock traded up $0.76 during trading hours on Wednesday, hitting $12.09. The stock had a trading volume of 1,028,349 shares, compared to its average volume of 1,042,863. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a market cap of $589.30 million, a PE ratio of -2.44 and a beta of 0.38. The company has a 50-day moving average of $14.80 and a two-hundred day moving average of $9.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Wall Street Analyst Weigh In

Several research firms have commented on QURE. Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus boosted their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. RTW Investments LP bought a new stake in uniQure in the 3rd quarter valued at $49,000. Atria Investments Inc bought a new position in uniQure during the third quarter worth about $53,000. Quarry LP acquired a new stake in uniQure during the third quarter valued at approximately $58,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of uniQure in the 3rd quarter worth approximately $69,000. Finally, Twin Tree Management LP bought a new position in shares of uniQure during the 4th quarter worth approximately $77,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.